World AI Cannes Festival: must-see speakers in 2023
The World AI Cannes Festival will take place in Cannes on February 9, 10 and 11 2023. This is the top world event dedicated exclusively to AI, tech leaders innovating in AI and the economic, human and societal issues that will impact our lives in the short term.
The event is a chance to get up to speed on the current marketplace, learn from the best experts and to meet decision-makers and top business leaders. Many notable speakers will deliver presentations and lead strategic conferences, think-tank workshops, exhibition stands and networking sessions.
Spotlight on the major speakers for 2023
The WAICF is an opportunity for artificial intelligence professionals and experts , whether from professional backgrounds, research or public administrations, to meet and exchange views on developments in the sector.
The 100+ international speakers at the WAICF in 2023 will include:
- Yann Lecun, Vice-President and Chief AI Scientist, Meta AI
- Joann Stonier, Chief Data Officer, Mastercard
- Wolfgang Hauner, Head of Group Data Analytics, Allianz
- Saeed Contractor, Global Head of Intelligent Automation COE, Uber
- Manuela M. Veloso, Head, J. P. Morgan Chase AI Research
- Xavier Lagardere, Chief Data Officer, Vice President Data Strategy and Transformation, Lufthansa Group
- Stuart Russell, Professor of Computer Science and Michael H. Smith and Lotfi A. Zadeh Chair in Engineering, University of California, Berkeley
- Alberto Prado, Vice-President, Global Head of R&D Digital & Partnerships, Unilever
- Divya Dwivedi, Advocate, Supreme Court of India
- Aidan Gomez, Co-Founder and CEO, Cohere
- Thomas Wolf, Co-Founder and Chief Science Officer, Hugging Face
- John Kamara, Founder and CEO/founder, Adanian Labs/AI Center of Excellence (AICE)
- Michael Kearns, Amazon Scholar, University of Pennsylvania
- Michaela Schutt, SVP, Head of Global Talent Acquisition Ecosystem, Siemens
- Nozha Boujemaa, Global VP - Digital Ethics and Responsible AI, IKEA Retail
- Oren Etzioni, CEO, Allen Institute for AI
The Festival will provide an overview of AI in all its diversity through 5 key conference tracks:
- AI FOR SOCIETY: Understand the benefits of AI for society and our planet, and the challenges that must be met.
- AI TODAY AND TOMORROW: Explore what AI can do today, and picture what future innovations will offer tomorrow's society and organizations.
- AI STRATEGY: Get key insights to improve your AI strategy and take your business to the next level.
- AI TECHNOLOGY: Learn how best to use the different AI technologies, and shape your innovation mindset with top-level speakers.
- AI APPLICATIONS: Get an overview of the advances organizations can make using AI, through focuses on various industries.
Full list of conferences and speakers
Get accreditation through the media pass site
About World AI Cannes Festival
The World AI Cannes Festival brings together industry experts, professionals, and the general public to attend exhibitions, workshops, happenings, conferences, networking and meet-ups with an international dimension. The rich and varied program highlights the latest AI applications in business and in everyday life. A unique opportunity for national and international institutions, associations, businesses and start-ups across the world to meet their target audiences, highlight their expertise and demonstrate their commitment to ethical and sustainable AI.
The original source-language text of this announcement is the official, authoritative version. Translations are provided as an accommodation only, and should be cross-referenced with the source-language text, which is the only version of the text intended to have legal effect.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230123005541/en/
Contact information
Press contacts WAICF 2023
Profile Agency –
waicf@agence-profile.com
Jennifer Loison – 06 10 22 52 37 | Shérazade El Houari – 06 22 35 69 79
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Kinaxis Positioned Highest on Ability to Execute in the Gartner® Magic Quadrant™ for Supply Chain Planning Solutions26.4.2024 19:03:00 EEST | Press release
Kinaxis® Inc. (TSX:KXS), a global leader in end-to-end supply chain orchestration, today announced it has been named a Leader in the 2024 Gartner® Magic Quadrant™ for Supply Chain Planning Solutions. Of the 20 vendors evaluated, Gartner positioned Kinaxis highest on Ability to Execute, marking the company’s 10th consecutive Leaders Quadrant within the report, a complimentary copy of which can be downloaded here. Kinaxis attributes its position to its patented concurrency approach and a proven track record of delivering innovative solutions against the foundation of its leading vision through the use of advanced technology such as AI, ML, and an intuitive user experience. Bolstered by a rich ecosystem of third-party implementation partners, Kinaxis continues to demonstrate that regardless of a customer’s industry, size, or maturity level, the company can be counted on to seamlessly orchestrate supply chain networks end-to-end from strategic planning to last-mile delivery. The recognitio
Vertex Announces European Commission Approval for KALYDECO® to Treat Infants With Cystic Fibrosis Ages 1 Month and Older26.4.2024 18:43:00 EEST | Press release
Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for the label expansion of KALYDECO® (ivacaftor) for the treatment of infants down to 1 month of age with cystic fibrosis (CF) who have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: R117H, G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R. “Today’s approval is an important milestone for the cystic fibrosis community. Treating CF early in life can potentially slow the progression of the disease, which is why it is so important to start treatment from a very young age,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. As a result of existing access agreements in Austria, Czech Republic, Denmark, Ireland, Norway, Sweden, and The Netherlands, eligible patients will have access to the expanded indication of KALYDECO® (ivacaftor)
Suzano 2023 annual report on Form 20-F26.4.2024 18:22:00 EEST | Press release
Suzano S.A. (B3: SUZB3 | NYSE: SUZ) informs that its 2023 Annual Report on Form 20-F was filed today with the U.S. Securities and Exchange Commission. Holders of the Company’s equity securities can receive hard copies of the Annual Report, including its audited financial statements, without charge by request directed to: ri@suzano.com.br. This document is also available on Suzano’s website (http://ir.suzano.com.br/). For further information, please contact our Investor Relations Department: Phone: (+55 11) 3503-9330 E-mail: ri@suzano.com.br View source version on businesswire.com: https://www.businesswire.com/news/home/20240426289818/en/ Contact information Hawthorn Advisors suzano@hawthornadvisors.com
Takeda Receives Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer26.4.2024 15:30:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of fruquintinib, a selective inhibitor of vascular endothelial growth factor receptors (VEGFR) -1, -2 and -3 for the treatment of adult patients with previously treated metastatic colorectal cancer (mCRC). The European Commission (EC) will consider the CHMP positive opinion when determining the potential marketing authorization for fruquintinib for mCRC throughout the European Union (EU), Norway, Liechtenstein and Iceland. If approved, fruquintinib will be the first and only selective inhibitor of all three VEGF receptors approved in the EU for previously treated mCRC.1,2 “People living with metastatic colorectal cancer in the European Union currently have limited treatment options, which can lead to poor outcomes. With this positive opinion for fruquintinib, we are one step closer to potentially offering patients a new
MEDIA ALERT: Wolters Kluwer expert comments on European Parliament vote to pass amendment implementing Basel III reforms26.4.2024 15:00:00 EEST | Press release
The European financial landscape saw a milestone event this week, as the EU Parliament passed the Amendment to Regulation (EU) No 575/2013, implementing the Basel III finalization within Europe. This monumental step forward comes with the adoption of the Capital Requirements Regulation (CRR3) amendments, which are part of a broader legislative package, including amendments to Directive 2013/36/EU, known as the Capital Requirements Directive or CRD. Jeroen Van Doorsselaere, Vice President of Global Product & Platform Management, Wolters Kluwer FRR, said: “The adoption of the Capital Requirements Regulation (CRR3) amendments represents a landmark change for the banking industry, designed to strengthen the framework for risk-based capital requirements and address ESG risks. “This is a major overhaul of the capital requirements framework, impacting various aspects, including credit risk, operational risk, market risk, and the capital floor. Whereas other significant jurisdictions, includin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom